This paper describes further pharmacological characterization of the decidual prostagl andi n\x=req-\ releasing oxytocin receptors and the myometrial uterotonic oxytocin receptors in the uterus of the pregnant rat. The effects of oxytocin, arginine-vasopressin and their related agonists and antagonists on the release of PGF2\g=a\ were studied in vitro on isolated uteri from rats on day 19\p=n-\20of pregnancy that had been incubated in Krebs buffer, pH 7.4, at 37\s=deg\C.The concentration of PGF2\g=a\ in the media was measured using specific radioimmunoassays. It was found that the decidual and myometrial oxytocin receptors exhibit different ligand specificities. Of the agonists tested, oxytocin and arginine-vasopressin stimulated PGF2\g=a\ release in a dose-dependent manner. Arginine-vasopressin has only 3% of the uterotonic potency of oxytocin, but was found to have 16% of its PGF2\g=a\-releasing activity.
Introduction
The mechanism that triggers the onset of labour is not known.
The onset of parturition is preceded by a marked increase in the concentrations of oxytocin receptors (Alexandrova and Soloff, 1980; Soloff, 1985) and the formation of gap junctions (Garfield el al, 1980; Verhoeff and Garfield, 1986) in the myometrium.
The development of these two biomolecular events may have an important role in the initiation of labour. Oxytocin has a dual action in the uterus: a uterotonic action on myometrial cells and a prostaglandin-releasing action on endometrial and decidual cells (Chan, 1980; Fuchs et al, 1982) . We have shown that oxytocin receptors and gap junctions in the pregnant rat are stimulated by prostaglandin F2tl (PGF2(i), while inhibiting prostaglandin synthesis suppresses their formation and delays the onset of labour (Chan et al, 1991;  Chan and Chen, 1992) .
Others have demonstrated that uterine tissues express the oxytocin gene during pregnancy, and that the rate of ex¬ pression increases markedly near term (Lefebvre et al, 1992 (Lefebvre et al, , 1993 Chibbar et al, 1993) . These findings suggest that a paracrine or autocrine oxytocin system is involved in initiating labour. We postulate that oxytocin may regulate its own receptor formation and gap junction development in the myometrium via its PGF2(1-releasing action in the endometrium and decidua. Preliminary findings showed that myometrial and decidual oxytocin receptors in the uterus of pregnant rats could be differentiated by oxytocin antagonists into two subtypes (Chan et al, 1993) . Presently available oxytocin antagonists may block only the uterotonic action or may block both the uterotonic and PGF2a-releasing actions of oxytocin. Delineat¬ ing the two oxytocin receptor subtypes and their ligand specificities is important both for the fundamental study of the action of oxytocin and to the clinical management of preterm labour. Characterizing the two uterine oxytocin receptor sub¬ types could lead to the development of myometrial-selective and endometrialor decidual-selective oxytocin antagonists.
Oxytocin antagonists selective for different receptor subtypes would provide powerful probes to investigate the role of oxytocin in the initiation of labour, and potential tocolytic agents for the treatment of preterm labour.
In this paper, we report further studies on the characteriz¬ ations of the myometrial uterotonic oxytocin receptors and the decidual prostaglandin-releasing oxytocin receptors in preg¬ nant rats. We present data showing that the two oxytocin receptor subtypes can be differentiated not only by appropriate oxytocin antagonists but also by their affinity and specificities for agonists.
Materials and Methods

Materials
The following oxytocin and vasopressin agonists and antagonists were used (with the exceptions noted below, these were synthesized in the laboratory by M. Manning): l-deamino-[8-D-arginine]vasopressin (dDAVP) (Zaoral et al, 1967; Manning et al, 1976) ; [4-threonine, 7-glycine]oxytocin ([Thr4, Gly7]OT) (Lowbridge et al, 1977) ; 1-deaminopenicillamine [2-0-methyl-tyrosine]ornithine-vasotocin (dP [Tyr-(Me)2]OVT) (Sawyer et al, 1980) (Manning et al, 1989 (Chan et al, 1986 
Animals
Pregnant Wistar rats, 60-70 days old, were purchased from Hilltop Laboratory Animals (Scottsdale, PA). Rats were mated in the morning and were examined in the afternoon for the presence of vaginal plugs (presence of plug indicated day 1 of pregnancy). Those found with plugs were identified, separated, and delivered to us on day 13 of pregnancy. The rats were housed individually in shoebox cages in our central animal care facility under a controlled photoperiod and air-conditioning.
Water and food were freely available. The use of animals in this protocol was approved by the Institutional Animal Care and Use Committee.
Experimental protocol
The effects of oxytocin agonists and antagonists on uterine PGF2a release in vitro were determined on isolated uteri from rats on day 19-20 of pregnancy. Rats were killed by cervical dislocation and the uterine horns quickly removed and placed in ice-cold Krebs-bicarbonate buffer at pH 7.4. The uterine horns were cut open and fetal tissues removed. Each uterine horn was divided longitudinally in half over the placental attachment sites, forming a matched pair. Thus, four matched tissues were obtained from each rat. Each uterine tissue was rinsed clean in buffer at 37°C, and was hung in an incubation chamber under a tension of 2 g. The tissues were incubated in 20 ml Krebs buffer that was aerated continuously with 95% 02 and 5% C02 at 37°C After 20 min, the experimental incubation period was started. The incubation medium was withdrawn and replaced at pregnancy Each point on the dose-response curves represents the mean value of at least three expenments ± SHM. The dashed line marks the relative potencies of the agonists; that is, the dose reared o increase the rate of release to 50% more than the control basal rate.
Extraction and radioimmunoassays of PGF2a
PGF2[1 from each incubation sample was extracted and eluted with ethyl acetate through a Sep-Pak CI8 cartridge (Waters, Milford, MA) . The extracts were dried at 40°C under N2 and the residue stored at -20°C until used for radioimmunoassay.
Details of the extraction and radioimmunoassay procedures were described by Chan (1987) . PGF2a concentrations were determined in each sample and in duplicate. The anti-PGF2a antibody used was highly specific, with no significant crossre¬ actions (< 0.5%) with other prostaglandins present in the uterus. The sensitivity of the radioimmunoassay was 15 pg per assay tube. The intra-assay coefficient of variation was < 10% and the interassay coefficient of variation was < 15%.
In vitro oxytocin and anti-oxytocin assays In vitro oxytocin assays were performed on isolated uteri from Wistar rats that had been pretreated the afternoon before with 50 µg diethylstilboestrol in oil per rat injected s.c.
Mg2+-free van Dyke-Hasting solution (Munsick, 1960) was used as the bathing medium. Agonistic potencies were deter¬ mined against the USP standard using the four-point bioassay design (Holton, 1948) . Antagonistic potencies of the oxytocin antagonists were measured against oxytocin and expressed as pA2 values (Schild, 1947) .
Statistical analyses
All data were expressed as sample means + sem and analysed by analysis of variance. Significant differences between sample means were analysed by paired Student's t test at the = 0.05 level.
Results
Effects of oxytocin/vasopressin agonists on PGF2a release in vitro in the uteri of pregnant rats
The PGF2a-releasing activity of the four agonists (oxytocin and its uterotonic-selective analogue [Thr4, Gly7]OT; and arginine-vasopressin and its antidiuretic-selective analogue dDAVP) were determined in vitro in the rat uterus on day 19-20 of pregnancy.
Oxytocin, arginine-vasopressin and dDAVP stimulated PGF2a release in a dose-dependent manner (Fig. 1 doses of up to 300 ng ml~: (Fig. 2) .
There was no apparent correlation between the uterotonic and the PGF2il-releasing activities of the peptides (Table 1) .
Effects of oxytocin antagonists on PGF2a release in vitro
The five potent oxytocin antagonists (anti-oxytocic) were examined for their effects on PGF2a release and their antagon¬ ism of the PGF2a-releasing activity of oxytocin in vitro in rat uteri on day 19-20 of pregnancy. The anti-oxytocin potencies of these five oxytocin antagonists range from pA2 values of 7.30 to 7.95. The concentrations of the oxytocin antagonists used in the experiments (30-750 ng ml-1) cover the halfmaximal to maximal anti-uterotonic doses of these antagonists in the pA2 bioassay. They were effective inhibitory doses of the uterotonic response to the dose of oxytocin (2-4 ng ml~* ) used to stimulate PGF2ll release in the pregnant rat uterus.
In confirmation of preliminary studies (Chan et al, 1993) , P[Phe(Me)2, Thr4]OVT was found to be a partial oxytocin antagonist and desGly-NH2, d(CH2)5[Tyr(Me)2, Thr4]OVT a full oxytocin antagonist. P[Tyr(Me)2, Thr4]OVT, a close congener of P[Phe(Me)2, Thr4]OVT, also acts as a partial oxytocin antagonist. It blocked the uterotonic response to oxytocin but stimulated PGF2a release ( Table 2) . The PGF2(I-releasing dose-response curves of these two partial oxytocin antagonists are shown (Fig. 1 (Fig. 3 ).
Discussion
In one of our early studies, we found that treating pregnant rats during the last 3 days of gestation with P[Phe(Me)2, Thr4]OVT, a long-acting oxytocin antagonist, significantly prolonged the duration of parturition, but did not delay the onset of labour or suppress oxytocin receptor and gap junction formation (Chan et al, 1991; Chan and Chen, 1992 ). Subsequently, we deter¬ mined that P[Phe(Me)2, Thr4]OVT was a partial oxytocin antagonist, which blocked the uterotonic action of oxytocin but had agonistic action on decidual receptors stimulating PGF2a release (Chan et al, 1993) . This could account for the failure of this antagonist to suppress oxytocin receptor for¬ mation and delay the onset of labour. The study reported here provided further evidence that the myometrial and decidual oxytocin receptors represent two subtypes. The myometrial and decidual oxytocin receptors each had different ligand specificities for agonists and antagonists. To study the effects of agonists, we compared the uterotonic and PGF2(J-reIeasing potencies of oxytocin and [Thr4, Gly7]OT, a highly potent and selective uterotonic oxytocin analogue, and of arginine-vasopressin and dDAVP, a highly potent and (Manning et . 1976; Lowbridge et al, 1977) . Concentrations that increased the release of prostaglandins by 1.5 times the basal rate in isolated rat uteri on day 19-20 of pregnancy incubated in Krebs buffer at 37°C. cAssayed in 0.5 mmol Mg2+ 1~\ All assays of prostaglandin release were with Mg2+. of the uterotonic activity of oxytocin but was found to have 16% of the PGF2(I-releasing activity of oxytocin. [Thr4, Gly7]OT, the highly selective uterotonic oxytocin agonist with negligible vasopressor (Vla receptor) or antidiuretic (V2 recep¬ tor) activities and nearly two times more potency than oxyto¬ cin in uterotonic activity, when assayed in 0.5 mmol Mg + 1( Lowbridge et al, 1977) , had no detectable PGF2a-releasing activity at a dosage 30 times higher than that of oxytocin. dDAVP is a highly potent and selective V2 agonist (Zaoral et al, 1967; Manning et al, 1976) . It has an antidiuretic activity of 1200 U mg~: versus 320 U mg~ for argininevasopressin, but a uterotonic activity of only 10% of that of arginine-vasopressin and 0.3% of that of oxytocin (Manning et al, 1976) . Its PGF2a-releasing activity was found to be equal to that of arginine-vasopressin. The effects of the oxytocin antagonists P[Phe(Me)2, Thr4]OVT and its close congener P[Tyr(Me)2, Thr4]OVT (Chan et al, 1986 , and of desGly-NH2, d(CH2)5[Tyr(Me)2, Thr4]OVT and its nontruncated structure d(CH2)5[Tyr(Me)2, Thr4]OVT (Manning et al, 1989) , and dP[Tyr(Me)2]OVT (Sawyer et al, 1980) , were also compared. We confirmed our preliminary findings (Chan et al, 1993) that P[Phe(Me)2, Thr4]OVT is a partial oxytocin antag¬ onist and desGly-NH2, d(CH2)5[Tyr(Me)2, Thr4]OVT is a full oxytocin antagonist. P[Tyr(Me)2, Thr4]OVT, like its Phe(Me)2 congener, was also found to be a partial oxytocin antagonist, both of these partial antagonists blocked the uterotonic action of oxytocin but stimulated PGF2a release in the isolated pregnant rat uterus. However, their PGF2(I-releasing potencies were 2-3 orders of magnitude weaker than oxytocin.
The peptides d(CH2)5[Tyr(Me)2, Thr4]OVT and dP[Tyr-(Me)2]OVT, like the truncated desGly-NH2, d(CH2)5[Tyr(Me)2, Thr4]OVT, were found to be full oxytocin antagonists, which blocked both the uterotonic and prostaglandin-releasing actions of oxytocin. However, all three oxytocin antagonists were much more potent in antagonizing the uterotonic action than the PGF2[i-releasing action of oxytocin. The concen¬ trations of the antagonists used in the anti-prostaglandinrelease assays (30-750 ng ml~T ) were at least a thousand times higher than those used in the pA2 anti-uterotonic assays. The dose range used in the anti-prostaglandin-release assays pro¬ duced maximal inhibitions of the oxytocin-induced contrac¬ tions in the isolated pregnant uterus. The high doses required to block the oxytocin-induced PGF2(1 release indicate that these oxytocin antagonists are poor ligands for the decidual PGF2areleasing oxytocin receptors.
The striking differential effects between the different oxyto¬ cin antagonists on uterotonic inhibition and inhibition of PGF2a release and the lack of PGF2(1-releasing activity of the highly potent and selective oxytocin agonist [Thr4, Gly7]OT strongly support our postulate that the myometrial uterotonic oxytocin receptors and the endometrial/decidual prostaglandin-releasing oxytocin receptors represent two distinct subtypes. We pro¬ pose, as suggested by Chan et al (1993) , that the myometrial uterotonic oxytocin receptors be designated as the OT:a sub¬ type and the endometrial/decidual PGF2o-releasing oxytocin receptors as the OTIb subtype. Although the number of ago¬ nists and antagonists investigated in this study was too small to allow a characterization of the ligand specificities of the two receptor subtypes, the findings do appear to suggest that deleting the amino-terminal amino group may be a requirement for inhibiting prostaglandin release. It also appears that a struc¬ ture selective for V2 receptors may enhance binding to decidual oxytocin receptors, as suggested by the relative PGF2ll-releasing activity of arginine-vasopressin and dDAVP to their respective uterotonic activities. Further analysis of structure-activity re¬ lationships could lead to the discovery of decidual-selective and myometrial-selective oxytocin agonists and antagonists.
Premature birth is a major medical, societal and economic problem. Premature labour affects nearly 10% of pregnancies, and premature birth is the leading cause of neonatal mortality and morbidity in developed countries (Vital Statistics of US, 1982; Main, 1988) . Safe and effective therapeutic intervention of preterm labour has yet to be developed. The mechanism that triggers the onset of labour is poorly understood. The marked increases in myometrial oxytocin receptor concentrations and gap junction densities at term (Soloff, 1985; Verhoeff and Garfield, 1986; Chan et al, 1991; Chan and Chen, 1992) and the recent new findings that the pregnant uterus is a major site of oxytocin synthesis at term (Lefebvre et al, 1992 (Lefebvre et al, , 1993 Chibbar et al, 1993) suggest that a paracrine or autocrine oxytocin system may play an important role in the initiation of labour. The identification of the two oxytocin receptor subtypes in the uterus with different ligand specificities has important impli¬ cations both for our understanding of the mechanism of initiation of labour and for the clinical application of oxytocin antagonists in the treatment and prevention of preterm labour.
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